AAV9 vector-based miR-132 therapy (Japan National Institute of Neuroscience)

N/A

Report date: 2025/01/26 15:58:21

Base Information

Drug NameAAV9 vector-based miR-132 therapy (Japan National Institute of Neuroscience)

Drug Alias NameAAV8 gene therapy (Gordian Biotechnology)adeno-associated virus (AAV) serotype rh.10 vector carrying NPC2 HA peptide (Weill Medical College of Cornell University)gene therapy (Gordian Biotechnology)huntingtin gene-targeted AAV-microRNA (Genzyme)

ClassificationBiologics

Mechanisms of ActionFibroblast growth factor 19 stimulants

TargetsFibroblast growth factor 19

Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesGordian Biotechnology Inc

China Registration ClassN/A

Develop Information

Active CompaniesGordian Biotechnology Inc

Inactive CompaniesN/A

Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Inactive IndicationsN/A

Other Information

ATC CodeN/A